Albert Vanderlaan is a partner in Orrick’s Technology Companies Group. He works with public and private companies, venture capital firms and investment banks focused on the life sciences and high-growth technology sectors.
Albert is involved in a broad range of corporate legal engagements for high growth technology companies, including venture financings, public offerings, private and public company securities law compliance matters, de-SPAC transactions, public company disclosure obligations, mergers and acquisitions and COVID-19 related matters (including public company disclosure obligations and Paycheck Protection Act eligibility and compliance matters) . He also regularly advises private and public companies and their board of directors on corporate governance issues. Albert's clients include private and public companies in the life sciences (including, among others, immuno-oncology, gene therapy, restorative cell therapy and medical device companies), real estate, finance, automotive and Internet related industries. He also represents underwriters in initial public offerings, follow-on offerings and PIPE offerings and venture capital firms in a variety of investment transactions.
Momentus Inc. in its pending combination with Stable Road Acquisition Corp., a SPAC sponsored by Stable Road Capital ($1.2 billion)
Luminar Technologies, Inc. in its business combination with Gores Metropoulos, Inc., a SPAC sponsored by affiliates of The Gores Group, LLC and Metropoulos & Co. ($3.4 billion), which closed in December 2020
Fisker Inc. in its business combination with Spartan Energy Acquisition Corp., a SPAC sponsored by an affiliate of Apollo Global Management, Inc. ($2.9 billion), which closed in October 2020
Histogenics Corporation in its reverse merger with Ocugen, Inc.*
A syndicate of institutional investors in the pre-IPO convertible note financing of Phathom Pharmaceuticals, Inc.*
ARMO BioSciences, Inc. in its acquisition by Eli Lilly for $1.6 billion*
Vanda Pharmaceuticals Inc. in its $101 million follow-on public offering*
Histogenics Corporation in its $17 million follow-on public offering*
Histogenics Corporation in its $6.325 million registered direct offering*
Synchronoss Technologies, Inc. in its sale of Intralinks Holdings, Inc. for $977 million*
Partner Therapeutics, Inc. in its acquisition of assets related to Leukine from sanofi-aventis U.S. LLC*
Synchronoss Technologies, Inc. in its acquisition of Intralinks Holdings, Inc. for $821 million*
REGENXBIO Inc. in its $250 million IPO*
Synchronoss Technologies, Inc. in its $230 million offering of 0.75% senior convertible notes*
Vitae Pharmaceuticals, Inc. in its acquisition by Allergan for $639 million*
*Please note: Albert's experience includes that prior to joining Orrick.
Please do not include any confidential, secret or otherwise sensitive information concerning any potential or actual legal matter in this e-mail message. Unsolicited e-mails do not create an attorney-client relationship and confidential or secret information included in such e-mails cannot be protected from disclosure. Orrick does not have a duty or a legal obligation to keep confidential any information that you provide to us. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.
By clicking "OK" below, you understand and agree that Orrick will have no duty to keep confidential any information you provide.